Publications by authors named "Huaxiang Liu"

Article Synopsis
  • - The study aimed to evaluate the effectiveness and safety of ivarmacitinib, a JAK 1 inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) who did not respond adequately to standard treatments.
  • - Participants were divided into three groups to receive either placebo, ivarmacitinib 4 mg, or 8 mg once daily, with primary outcomes measured after 24 weeks based on 20% improvement in RA symptoms (ACR20).
  • - Results showed significantly higher improvement rates in those taking ivarmacitinib compared to placebo, with manageable safety concerns, indicating it could be a promising option for this patient population.
View Article and Find Full Text PDF

This retrospective study aimed to investigate differences in clinical characteristics between different antibody phenotypes in patients with dermatomyositis (DM). Two hundred and ninety-three patients with DM were included in this study from September 2018 to September 2023. We collected basic clinical data from the patients, using statistical methods to analyze the clinical characteristics, and used survival analysis and COX regression to assess the prognosis of the patients.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the efficacy and safety of the biosimilar BAT1806/BIIB800 compared to the reference drug tocilizumab (TCZ) in patients with moderate-to-severe rheumatoid arthritis over a treatment period of 24-48 weeks.
  • Results showed that the effectiveness of both treatments was similar, with high response rates (ACR20), along with comparable safety and immunogenicity profiles across treatment groups.
  • Overall, the study concluded that BAT1806/BIIB800 has similar therapeutic outcomes to TCZ, supporting its use as a treatment option for rheumatoid arthritis patients.
View Article and Find Full Text PDF

Accurate liver tumor segmentation is crucial for aiding radiologists in hepatocellular carcinoma evaluation and surgical planning. While convolutional neural networks (CNNs) have been successful in medical image segmentation, they face challenges in capturing long-term dependencies among pixels. On the other hand, Transformer-based models demand a high number of parameters and involve significant computational costs.

View Article and Find Full Text PDF

Objectives: The current study is to accelerate the understanding of how tofacitinib works in patients with rheumatoid arthritis (RA) due to the lack of relevant information.

Method: We selected ten patients with active RA and obtained the expression profile for their peripheral blood mononuclear cells before and after the tofacitinib treatment by RNA sequencing. The gene set enrichment analysis was conducted, and the significantly enriched gene sets were identified.

View Article and Find Full Text PDF

Background: Biosimilars provide an opportunity to address unmet medical need by expanding access to biological treatments. This study aimed to show equivalent efficacy, and comparable safety, immunogenicity, and pharmacokinetic profiles of a proposed tocilizumab biosimilar BAT1806/BIIB800, to reference tocilizumab, in participants with rheumatoid arthritis with an inadequate response to methotrexate.

Methods: This phase 3, multicentre, randomised, double-blind, active-controlled, equivalence study comprised a 24-week initial treatment period (results reported here) and a 24-week secondary treatment period.

View Article and Find Full Text PDF

Objectives: This phase 2b, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of telitacicept, a novel fusion protein that neutralises signals of B lymphocyte stimulator and a proliferation-inducing ligand, in active systemic lupus erythematosus (SLE).

Methods: Adult patients with active SLE (n=249) were recruited from 29 hospitals in China and randomised 1:1:1:1 to receive subcutaneous telitacicept at 80 mg (n=62), 160 mg (n=63), 240 mg (n=62) or placebo (n=62) once weekly in addition to standard therapy. The primary endpoint was the proportion of patients achieving an SLE Responder Index 4 (SRI-4) response at week 48.

View Article and Find Full Text PDF

The objectives of this study were to screen for latent tuberculosis infection (LTBI) among patients with systemic lupus erythematosus (SLE) using the T-SPOT.TB assay and to identify factors affecting the assay results. SLE patients were enrolled from 13 tertiary hospitals in eastern, central, and western China from September 2014 to March 2016 and were screened using the T-SPOT.

View Article and Find Full Text PDF

The segmentation of pepper leaves from pepper images is of great significance for the accurate control of pepper leaf diseases. To address the issue, we propose a bidirectional attention fusion network combing the convolution neural network (CNN) and Swin Transformer, called BAF-Net, to segment the pepper leaf image. Specially, BAF-Net first uses a multi-scale fusion feature (MSFF) branch to extract the long-range dependencies by constructing the cascaded Swin Transformer-based and CNN-based block, which is based on the U-shape architecture.

View Article and Find Full Text PDF

Objectives: Although tofacitinib has been confirmed to have good efficacy and safety in the treatment of rheumatoid arthritis (RA), the relevant mechanism at the whole transcriptome level has not yet been revealed. In this study, peripheral blood mononuclear cells (PBMCs) from patients with active RA before and after tofacitinib treatment were analysed using whole transcriptome sequencing technology.

Methods: Fourteen patients with active RA were selected to detect the alterations of mRNAs, lncRNAs, circRNAs, and miRNAs in PBMCs before and after tofacitinib treatment using whole transcriptome sequencing.

View Article and Find Full Text PDF

Objectives: The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate.

Methods: We conducted a randomized, double-blinded, parallel, positive control design, multicenter study, with a stable dose of methotrexate. Patients were enrolled randomly with a ratio of 1:1 to receive intravenously CMAB008 3 mg/kg or innovator infliximab 3 mg/kg at weeks 0, 2, 6, 14, 22 and 30.

View Article and Find Full Text PDF

Black rockfish (Sebastes schlegelii) is a viviparous teleost fish whose spermatozoa were transferred into the female ovary cavity and stored for up to five months and then fertilized with the matured eggs. There is no clarity about the molecular characteristics of ovarian follicles during female sperm storage in Sebastes schlegelii. In this study, histological observation, transcriptomic analysis and hormone level detection were performed in ovaries at stages of pre-mating (PRM), post-mating (POM) and pre-fertilization (PRF).

View Article and Find Full Text PDF

Liver segmentation is a critical step in liver cancer diagnosis and surgical planning. The U-Net's architecture is one of the most efficient deep networks for medical image segmentation. However, the continuous downsampling operators in U-Net causes the loss of spatial information.

View Article and Find Full Text PDF

Background: To evaluate the efficacy and safety of HLX01, a rituximab biosimilar, as combination therapy with methotrexate in Chinese patients with active rheumatoid arthritis who had inadequate responses to methotrexate.

Methods: In this double-blind, placebo-controlled phase 3 trial, biologic-naïve patients with moderate-to-severe active rheumatoid arthritis and inadequate responses to methotrexate were randomized 2:1 to receive 1000 mg HLX01 or placebo intravenously on days 1 and 15. On the first day of weeks 24 and 26, patients in both groups received 1000 mg HLX01 via intravenous infusion.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the clinical equivalence of TQ-Z2301, a biosimilar to adalimumab, for treating active ankylosing spondylitis in Chinese patients.
  • Conducted across 19 centers in China, the trial involved 380 participants who received either TQ-Z2301 or adalimumab for 24 weeks, assessing response rates and various health outcomes.
  • Results showed that TQ-Z2301 had an ASAS20 response rate of 86.7%, which met the equivalence criteria compared to 80.7% for adalimumab, with similar safety and immunogenicity profiles in both groups.
View Article and Find Full Text PDF

Black rockfish is an economically important fish in East Asia. Little mention has been paid to the sperm cryopreservation in black rockfish. In this study, the optimal cryodiluent was selected from 48 combinations by detecting various sperm parameters.

View Article and Find Full Text PDF

Introduction: Baricitinib has been shown to improve patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) who are inadequate responders (IR) to conventional synthetic and biologic disease-modifying antirheumatic drugs (csDMARDs and bDMARDs, respectively). We assessed the ability of baricitinib 2-mg to maintain minimal clinically important differences (MCIDs) in PROs until week 24 among week 4 and 12 responders.

Methods: Data were from two phase 3 trials, RA-BUILD (NCT01721057; csDMARD-IR patients) and RA-BEACON (NCT01721044; bDMARD-IR patients).

View Article and Find Full Text PDF

Evidence of active tuberculosis (ATB) in patients with rheumatic diseases are research priorities but limited data from China have been reported. Research targeting patients not taking anti-TNF biologics are especially insufficient. We aimed to investigate the prevalence and risk factors of ATB in this at-risk population.

View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to compare the effectiveness of biosimilar HS016 and adalimumab (Humira) in treating patients with active ankylosing spondylitis (AS) using health questionnaires.
  • - Conducted as a multicenter, randomized, double-blind trial, patients received either HS016 or adalimumab every two weeks for 24 weeks, assessing health improvements over time.
  • - Both treatments showed significant symptom improvement in the first two weeks, with effects tapering off between weeks 2 and 12, suggesting HS016 as an economical alternative for treating AS in Chinese patients.
View Article and Find Full Text PDF

Background: Hyperhomocysteinemia is associated with autoimmune diseases such as ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Current findings regarding plasma/serum homocysteine (HCY) levels in AS patients are inconsistent. This study aims to systematically evaluate the association between circulating HCY levels and AS.

View Article and Find Full Text PDF
Article Synopsis
  • * A subanalysis focused on individual efficacy indicators like back pain and joint counts showed no significant differences between the two groups, except for faster improvements in back pain scores for the adalimumab group at some weeks.
  • * Overall, most efficacy indicators showed comparable changes for both treatments throughout the trial, with significant improvements noted from baseline measurements.
View Article and Find Full Text PDF

Objectives: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA) and has a large impact on the prognosis of RA, particularly among females, with an increased prevalence and severity compared with that of males. Here, we aimed to investigate the lncRNA profiles in peripheral blood mononuclear cells (PBMCs) from middle-aged female patients with RA-ILD to determine whether they could help diagnose RA-ILD.

Method: We collected PBMCs from middle-aged female healthy controls, and RA and RA-ILD patients, excluding those with known risk factors of RA-ILD, such as being elderly or male, smoking, and having a history of other diseases.

View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated the effectiveness and safety of a biosimilar drug (HS016) against the original adalimumab (Humira) in treating active ankylosing spondylitis over 24 weeks, using a double-blind, randomized method involving 648 patients in China.
  • - Results showed no significant differences in the primary endpoint (20% improvement in symptoms) between HS016 (87.5% response rate) and adalimumab (90.1% response rate), indicating HS016 is comparable to the original drug.
  • - Safety profiles were similar, with most side effects being mild to moderate, and the concentration levels of both drugs during treatment were found to be equivalent.
View Article and Find Full Text PDF

BACKGROUND The objective of this study was to detect the level of olfactory function in patients with systemic lupus erythematosus (SLE) and to explore the relationship between impaired olfactory function and anti-ribosomal P protein antibody (ARPA), disease duration, and age. MATERIAL AND METHODS The level of olfactory function in 65 patients with SLE and 50 healthy participants was detected using the Connecticut Chemosensory Clinical Research Center (CCCRC) method; serum ARPA levels in SLE patients and the healthy control group were detected by enzyme-linked immunosorbent assay (ELISA). RESULTS CCCRC scores in the active SLE group was lower than that in the inactive SLE and healthy control groups (P<0.

View Article and Find Full Text PDF

Background: The notion that proteasome inhibitor bortezomib (BTZ) induced intracellular oxidative stress resulting in peripheral neuropathy has been generally accepted. The association of mitochondrial dysfunction, cell apoptosis, and endoplasmic reticulum (ER) stress with intracellular oxidative stress is ambiguous and still needs to be investigated. The activation of activating transcription factor 3 (ATF3) is a stress-hub gene which was upregulated in dorsal root ganglion (DRG) neurons after different kinds of peripheral nerve injuries.

View Article and Find Full Text PDF